Osteoporosis Drugs Market to be Valued USD 20.17 Billion by 2026

Rising prevalence of osteoporosis and surge in geriatric population to drive the global osteoporosis drugs market.

According to TechSci Research report, “Global Osteoporosis Drugs Market By Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others), By Osteoporosis Disease Type (Primary Osteoporosis, Secondary Osteoporosis), By Route of Administration (Oral, Injectable, and Others), By Gender (Female, Male), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, Forecast & Opportunities, 2026”, the market is anticipated to grow at a healthy CAGR during the forecast period. The key factors propelling the growth of the global osteoporosis drugs market include rising prevalence of osteoporosis and surge in geriatric population around the world as they pose high susceptibility for osteoporosis. Growing adoption of sedentary lifestyle is also impacting bone health and thus, there is a rise in demand for osteoporosis drugs. Additionally, the increase in osteoporosis cases due to menopause in women is acting as a major growth driver for this market. In men, lifestyle associated factors such as smoking and alcohol abuse are found to promote osteoporosis. This is further expected to augment the global osteoporosis drugs market through 2026.

Moreover, increasing investment in R&D activities for the development of advanced new drug classes is also fueling the market growth. The wide range of pipeline drugs for approval in clinical trials are also expected to provide lucrative growth opportunities for osteoporosis drug manufacturers. However, the market is also prone to some challenges. Several side effects of osteoporosis drugs such as heartburn, nausea, irritable bowel syndrome and ulcers in the stomach are likely to hamper the market growth. Furthermore, the time-taking drug approval process is also anticipated to restrain the global osteoporosis drugs market growth.

Browse 182 Figures spread through 110 Pages and an in-depth TOC on “Global Osteoporosis Drugs Market”

https://www.techsciresearch.com/report/osteoporosis-drugs-market/5081.html

Global osteoporosis drugs market can be segmented based on disease type, drug class, route of administration, gender, distribution channel and region. Based on drug class, the market can be segmented into bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others. Among them, parathyroid hormone therapy are expected to register highest CAGR during the forecast period as they are increasingly being used to treat osteoporosis and have lesser side effects.

Based on route of administration, global osteoporosis drugs market can be segmented into oral, injectable, and others. Among them, the oral segment accounted for largest market share in 2020 owing to abundant availability of medications which are taken orally. However, the injectable segment is anticipated to witness fastest growth through 2026 owing to growing need for drugs that exhibit improved bioavailability rapid mode of action.

Major companies operating in global osteoporosis drugs market include F. Hoffmann-La Roche Ltd, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Novartis International AG, GlaxoSmithKline Plc, Merck & Co. Inc., Amgen, Inc., Allergan plc, Eli Lilly and Company, Radius Health, Inc., Sun Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited, Sanofi S.A., Abiogen Pharma S.p.A., Merrion Pharmaceuticals Plc., among others. The companies are undergoing new product development and collaborative research initiatives to increase their share in global osteoporosis drugs market.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=5081

Customers can also request for 10% free customization on this report.

“North America dominated the global osteoporosis drugs market in 2020 and is expected to hold its dominance through 2026 owing to rising prevalence of osteoporosis and easy availability of osteoporosis drugs in the region. However, Asia Pacific is anticipated to undergo fastest growth during the forecast period due to thriving life science industry and growing awareness about the benefits of osteoporosis drugs,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“Global Osteoporosis Drugs Market By Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others), By Osteoporosis Disease Type (Primary Osteoporosis, Secondary Osteoporosis), By Route of Administration (Oral, Injectable, and Others), By Gender (Female, Male), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, Forecast & Opportunities, 2026” has evaluated the future growth potential of global osteoporosis drugs market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global osteoporosis drugs market.

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: [email protected]